# Maximum Tolerated Dose, Safety and Efficacy of Docetaxel / Cisplatin + STI571

> **NCT02127372** · PHASE1,PHASE2 · TERMINATED · sponsor: **Duke University** · enrollment: 43 (actual)

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **DRUG:** Docetaxel, Cisplatin and STI571
- **DRUG:** Docetaxel
- **DRUG:** Cisplatin

## Key facts

- **NCT ID:** NCT02127372
- **Lead sponsor:** Duke University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2004-11
- **Primary completion:** 2010-06
- **Final completion:** 2010-12
- **Target enrollment:** 43 (ACTUAL)
- **Why stopped:** The study was closed due to poor accrual
- **Last updated:** 2014-09-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02127372

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02127372, "Maximum Tolerated Dose, Safety and Efficacy of Docetaxel / Cisplatin + STI571". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02127372. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*